ACLY and COVID-19: A significant proportion of severe and PAP COVID-19 patients exhibited aCL IgM/IgG and anti-B2GPI IgM/IgG positivity, with persistent low-level pro-thrombotic potential activity, highlighted by a sustained imbalance in the innate immune response and persistence of NETs markers [88].